Voyager Therapeutics received FDA IND clearance for VY-1706, an investigational gene therapy aimed at intracellular and extracellular tau for Alzheimer’s disease. The IND approval allows Voyager to move forward with clinical development plans tied to the program. Tau pathology remains a major therapeutic focus in neurodegeneration, and gene therapy approaches are increasingly positioned as attempts to reach both neuronal and extracellular tau pools. The clearance highlights regulatory willingness to engage with next-generation neurotropic platforms, though detailed trial design information was not provided in the report. For the market, IND clearance is an execution milestone that typically enables enrollment, manufacturing scaling, and site activation—key steps that determine the real pace of translational assets. Overall, the approval adds another tau-directed gene therapy option to the Alzheimer’s pipeline as sponsors compete for differentiation in delivery, expression, and mechanism.